Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search for Articles Submit an Article for Review
31 through 40 of 108

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : Genetic causes of hereditary pancreatic cancer: BRCA and beyond

Most relevant for: People diagnosed with pancreatic cancer

An update on hereditary pancreatic cancer presented at the annual American Society of Clinical Oncology meeting covered genes and lifetime risk. The update emphasized that all pancreatic cancer patients should be offered genetic counseling and testing. Genetic test results may impact treatment, screening for other cancers and risk to family members. (11/26/19)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Human Research

Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Most relevant for: Women newly-diagnosed with ovarian cancer

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation

The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

Study : Inherited mutations in metastatic breast cancer patients

Most relevant for: People with metastatic breast cancer

Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Study : Is it safe for BRCA mutation carriers to become pregnant following breast cancer?

Most relevant for: Women with a BRCA mutation who are considering pregnancy after breast cancer

New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies. (9/4/19)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : MRI or mammograms for detecting breast cancer in families with unknown genetic mutations?

Most relevant for: People with a personal or family history of cancer where no mutation has been found

MRI and mammograms are used together to detect breast cancer in high-risk women who test positive for a BRCA or other gene mutation that increases the risk for breast cancer. For women with a family history of breast cancer but no known genetic mutation, increased screening is recommended. But what method is best? A recent clinical trial in the Netherlands compared MRI and mammography for this population. (8/15/19)

Read More

Relevance: High

Research Timeline: Post Approval

Guideline : FDA asks Allergan to recall certain textured breast implants

Most relevant for: Women with, or considering breast reconstruction with implants

On July 25, 2019, the Food and Drug Administration requested that breast implant manufacturer Allergan recall its BIOCELL textured implants and expanders due to an association with a rare type of lymphoma called Breast Implant Associated Anaplastic Large Cell Lymphoma or BIA-ALCL. The FDA does not recommend removing implants for people who do not have disease symptoms. This XRAYS review updates information about this FDA recall. (7/29/19)

Read More

Relevance: High

Strength of Science: High

Research Timeline: Human Research

Study : Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

Most relevant for: People diagnosed with pancreatic cancer who have a BRCA mutation

Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19) 

Read More

Relevance: Medium-High

Quality of Writing: Medium-High

Personal Story : A young woman's story of genetic testing and risk-reducing mastectomy

Most relevant for: Young women of color with a BRCA mutation

Alejandra Campoverdi comes from a family with three generations of breast cancer. As a former White House aide and active educator in the Latina community, she has openly shared her story of genetic testing, her BRCA2 mutation and her plans for risk-reducing mastectomy at age 39. (6/6/19)

Este artículo está disponible en español.

Read More

Relevance: High

Research Timeline: Post Approval

Guideline : FDA approves an immunotherapy treatment for some patients with triple-negative breast cancer

Most relevant for: People with metastatic, triple-negative breast cancer

THIS INFORMATION HAS BEEN UPDATED: In August 2021 Roche voluntarily withdrew their FDA accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumours express PD-L1. 

The FDA approved the use of the immunotherapy drug atezolizumab (Tecentriq) in combination with the chemotherapy agent nab-paclitaxel (Abraxane) for certain patients with advanced triple-negative breast cancer. (5/26/19)

Read More